Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations
Justin A. Chen(Cornell University), Jonathan W. Riess(University of California Davis Medical Center)
Cited by 23
Related Papers
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|805
siRNA-directed inhibition of HIV-1 infection
|Nature Medicine|2002|777
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|670